Cargando…
Factors affecting use of magnesium sulphate for pre‐eclampsia or eclampsia: a qualitative evidence synthesis
BACKGROUND: Hypertensive disorders account for 14% of global maternal deaths. Magnesium sulphate (MgSO(4)) is recommended for prevention and treatment of pre‐eclampsia/eclampsia. However, MgSO(4) remains underused, particularly in low‐ and middle‐income countries (LMICs). OBJECTIVE: This qualitative...
Autores principales: | Eddy, KE, Vogel, JP, Zahroh, RI, Bohren, MA |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291451/ https://www.ncbi.nlm.nih.gov/pubmed/34520111 http://dx.doi.org/10.1111/1471-0528.16913 |
Ejemplares similares
-
Clinical pharmacokinetic properties of magnesium sulphate in women with pre‐eclampsia and eclampsia
por: Okusanya, BO, et al.
Publicado: (2015) -
Clinical practice patterns on the use of magnesium sulphate for treatment of pre‐eclampsia and eclampsia: a multi‐country survey
por: Long, Q, et al.
Publicado: (2016) -
Treatment of Eclampsia with Magnesium Sulphate
por: Quddus, M. A.
Publicado: (1946) -
Maternal outcomes of magnesium sulphate and diazepam use in women with severe
pre-eclampsia and eclampsia in Ethiopia
por: Kassie, Gizat M., et al.
Publicado: (2014) -
Eclampsia Treated with Intravenous Injection of Magnesium Sulphate Solution
por: Roy, S. K.
Publicado: (1941)